These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 9855701)

  • 1. Ryanodine receptors and their role in genetic diseases (review).
    Leeb T; Brenig B
    Int J Mol Med; 1998 Sep; 2(3):293-300. PubMed ID: 9855701
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ryanodine receptor type 1 (RyR1) possessing malignant hyperthermia mutation R615C exhibits heightened sensitivity to dysregulation by non-coplanar 2,2',3,5',6-pentachlorobiphenyl (PCB 95).
    Ta TA; Pessah IN
    Neurotoxicology; 2007 Jul; 28(4):770-9. PubMed ID: 17023049
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Malignant hyperthermia.
    MacLennan DH; Phillips MS
    Science; 1992 May; 256(5058):789-94. PubMed ID: 1589759
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impaired interaction between skeletal ryanodine receptors in malignant hyperthermia.
    Liang X; Chen K; Fruen B; Hu J; Ma J; Hu X; Parness J
    Integr Biol (Camb); 2009 Sep; 1(8-9):533-9. PubMed ID: 20023768
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The genetic basis of malignant hyperthermia.
    Moochhala SM; Tan WT; Lee TL
    Ann Acad Med Singap; 1994 Jul; 23(4):475-8. PubMed ID: 7979121
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ryanodine receptor mutations in malignant hyperthermia and central core disease.
    McCarthy TV; Quane KA; Lynch PJ
    Hum Mutat; 2000; 15(5):410-7. PubMed ID: 10790202
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduced threshold for store overload-induced Ca
    Chen W; Koop A; Liu Y; Guo W; Wei J; Wang R; MacLennan DH; Dirksen RT; Chen SRW
    Biochem J; 2017 Aug; 474(16):2749-2761. PubMed ID: 28687594
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Calcium release from sarcoplasmic reticulum is facilitated in human myotubes derived from carriers of the ryanodine receptor type 1 mutations Ile2182Phe and Gly2375Ala.
    Wehner M; Rueffert H; Koenig F; Olthoff D
    Genet Test; 2003; 7(3):203-11. PubMed ID: 14641996
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The genetic basis of malignant hyperthermia.
    MacLennan DH
    Trends Pharmacol Sci; 1992 Aug; 13(8):330-4. PubMed ID: 1329295
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Malignant hyperthermia: a pharmacogenetic disease of Ca++ regulating proteins.
    Nelson TE
    Curr Mol Med; 2002 Jun; 2(4):347-69. PubMed ID: 12108947
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heat- and anesthesia-induced malignant hyperthermia in an RyR1 knock-in mouse.
    Chelu MG; Goonasekera SA; Durham WJ; Tang W; Lueck JD; Riehl J; Pessah IN; Zhang P; Bhattacharjee MB; Dirksen RT; Hamilton SL
    FASEB J; 2006 Feb; 20(2):329-30. PubMed ID: 16284304
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dynamic alterations in myoplasmic Ca2+ in malignant hyperthermia and central core disease.
    Lyfenko AD; Goonasekera SA; Dirksen RT
    Biochem Biophys Res Commun; 2004 Oct; 322(4):1256-66. PubMed ID: 15336973
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genotype-Phenotype Correlations of Malignant Hyperthermia and Central Core Disease Mutations in the Central Region of the RYR1 Channel.
    Murayama T; Kurebayashi N; Ogawa H; Yamazawa T; Oyamada H; Suzuki J; Kanemaru K; Oguchi K; Iino M; Sakurai T
    Hum Mutat; 2016 Nov; 37(11):1231-1241. PubMed ID: 27586648
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Therapeutic effects of novel type1 ryanodine receptor inhibitor on skeletal muscle diseases].
    Yamazawa T; Kobayashi T; Kurebayashi N; Murayama T
    Nihon Yakurigaku Zasshi; 2022; 157(1):15-22. PubMed ID: 34980804
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Malignant hyperthermia and excitation-contraction coupling.
    Melzer W; Dietze B
    Acta Physiol Scand; 2001 Mar; 171(3):367-78. PubMed ID: 11412150
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutations in RYR1 in malignant hyperthermia and central core disease.
    Robinson R; Carpenter D; Shaw MA; Halsall J; Hopkins P
    Hum Mutat; 2006 Oct; 27(10):977-89. PubMed ID: 16917943
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional characterisation of the R2452W ryanodine receptor variant associated with malignant hyperthermia susceptibility.
    Roesl C; Sato K; Schiemann A; Pollock N; Stowell KM
    Cell Calcium; 2014 Sep; 56(3):195-201. PubMed ID: 25086907
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of a mutation in the ryanodine receptor 1 gene with equine malignant hyperthermia.
    Aleman M; Riehl J; Aldridge BM; Lecouteur RA; Stott JL; Pessah IN
    Muscle Nerve; 2004 Sep; 30(3):356-65. PubMed ID: 15318347
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel ryanodine receptor mutation and genotype-phenotype correlation in a large malignant hyperthermia New Zealand Maori pedigree.
    Brown RL; Pollock AN; Couchman KG; Hodges M; Hutchinson DO; Waaka R; Lynch P; McCarthy TV; Stowell KM
    Hum Mol Genet; 2000 Jun; 9(10):1515-24. PubMed ID: 10888602
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RYR1 mutations causing central core disease are associated with more severe malignant hyperthermia in vitro contracture test phenotypes.
    Robinson RL; Brooks C; Brown SL; Ellis FR; Halsall PJ; Quinnell RJ; Shaw MA; Hopkins PM
    Hum Mutat; 2002 Aug; 20(2):88-97. PubMed ID: 12124989
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.